WO2016071683A3 - Segmented rna genome viruses and their manipulation - Google Patents

Segmented rna genome viruses and their manipulation Download PDF

Info

Publication number
WO2016071683A3
WO2016071683A3 PCT/GB2015/053303 GB2015053303W WO2016071683A3 WO 2016071683 A3 WO2016071683 A3 WO 2016071683A3 GB 2015053303 W GB2015053303 W GB 2015053303W WO 2016071683 A3 WO2016071683 A3 WO 2016071683A3
Authority
WO
WIPO (PCT)
Prior art keywords
complementarity
rna genome
manipulation
segment
segmented rna
Prior art date
Application number
PCT/GB2015/053303
Other languages
French (fr)
Other versions
WO2016071683A2 (en
Inventor
Mark Boyce
Malcolm MCCRAE
Gillian PULLINGER
Original Assignee
The Pirbright Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Pirbright Institute filed Critical The Pirbright Institute
Publication of WO2016071683A2 publication Critical patent/WO2016071683A2/en
Publication of WO2016071683A3 publication Critical patent/WO2016071683A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12111Orbivirus, e.g. bluetongue virus
    • C12N2720/12134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12111Orbivirus, e.g. bluetongue virus
    • C12N2720/12161Methods of inactivation or attenuation
    • C12N2720/12162Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides a segmented virus which comprises a RNA genome comprising a first and a second segment which interact during virion assembly by base pairing between complementarity motifs on the first and second segments; wherein the complementarity motifs on the first and second segments are mutated such that base pairing is maintained between the first and second segment but such that the complementarity motif does not base pair with an equivalent interacting complementarity motif on a segment from a wild type virus.
PCT/GB2015/053303 2014-11-03 2015-11-03 Virus WO2016071683A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1419572.1A GB201419572D0 (en) 2014-11-03 2014-11-03 Virus
GB1419572.1 2014-11-03

Publications (2)

Publication Number Publication Date
WO2016071683A2 WO2016071683A2 (en) 2016-05-12
WO2016071683A3 true WO2016071683A3 (en) 2016-06-23

Family

ID=52118635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2015/053303 WO2016071683A2 (en) 2014-11-03 2015-11-03 Virus

Country Status (2)

Country Link
GB (1) GB201419572D0 (en)
WO (1) WO2016071683A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6805139B2 (en) 2014-11-13 2020-12-23 ウニヴァシテ デ ジュネーブUniversite De Geneve Trisegmental arenavirus as a vaccine vector
US10669315B2 (en) 2015-06-10 2020-06-02 Hookipa Biotech Gmbh HPV vaccines
LT3371316T (en) 2015-11-04 2022-11-25 Hookipa Biotech Gmbh Vaccines against hepatitis b virus
JP7157662B2 (en) 2015-11-12 2022-10-20 ホオキパ バイオテック ジーエムビーエイチ Arenavirus particles as cancer vaccines
CN110643740B (en) * 2019-10-15 2023-08-04 云南省畜牧兽医科学院 Real-time fluorescent quantitative RT-PCR detection primer, probe and detection kit for Pariemam serogroup virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CALVO-PINILLA EVA ET AL: "Recombinant vaccines against bluetongue virus", VIRUS RESEARCH, vol. 182, 25 November 2013 (2013-11-25), pages 78 - 86, XP028634088, ISSN: 0168-1702, DOI: 10.1016/J.VIRUSRES.2013.11.013 *
CATCHPOLE A P ET AL: "Alternative base pairs attenuate influenza A virus when introduced into the duplex region of the conserved viral RNA promoter of either the NS or the PA gene.", JOURNAL OF GENERAL VIROLOGY, vol. 84, no. 3, March 2003 (2003-03-01), pages 507 - 515, XP002754308, ISSN: 0022-1317 *
GAVAZZI CYRILLE ET AL: "A functional sequence-specific interaction between influenza A virus genomic RNA segments.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 8 OCT 2013, vol. 110, no. 41, 8 October 2013 (2013-10-08), pages 16604 - 16609, XP002754307, ISSN: 1091-6490 *
RAO C D ET AL: "Homologous terminal sequences of the genome double-stranded RNAs of bluetongue virus.", JOURNAL OF VIROLOGY MAY 1983, vol. 46, no. 2, May 1983 (1983-05-01), pages 378 - 383, XP002754309, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2016071683A2 (en) 2016-05-12
GB201419572D0 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
EP3681514A4 (en) Zika virus rna vaccines
WO2016071683A3 (en) Segmented rna genome viruses and their manipulation
EP3938379A4 (en) Hiv rna vaccines
EP3609534A4 (en) Broad spectrum influenza virus vaccine
EP3484510A4 (en) Modified foot-and-mouth disease virus 3c proteases, compositions and methods thereof
WO2016154579A3 (en) Crispr/cas-mediated gene conversion
WO2014195920A3 (en) Influenza virus reassortment
ZA202002249B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
WO2018006074A3 (en) Compounds and methods for modulating rna function
EP3419660A4 (en) Novel vaccines against zika virus
EP3197845A4 (en) High purity polysilocarb derived silicon carbide materials, applications and processes
WO2016055971A3 (en) Methods, systems and processes of de novo assembly of sequencing reads
WO2016115320A8 (en) Nucleic acid nanostructures with core motifs
WO2014141125A3 (en) Influenza b virus reassortment
WO2015168225A3 (en) Alkoxy polycarbonates, bisphenol monomers and methods of making and using the same
EP3846837A4 (en) Hiv or hcv detection with crispr-cas13a
EP3625349A4 (en) Modified viruses
EP3814509A4 (en) Influenza virus hemagglutinin mutants
WO2016081540A3 (en) Centrifugal fan and method
WO2016055647A3 (en) Method for preparing universal plasma
EP3545083A4 (en) Vaccines against infectious diseases caused by positive stranded rna viruses
EP3548457A4 (en) An improved process for the preparation of 2,3,3,3-tetrafluoropropene
WO2016009225A3 (en) Method for preventing or treating a protein aggregation disease
WO2015130843A3 (en) Phage wrapping
EP3130597A4 (en) Oligonucleotide having non-natural nucleotide at 5'-terminal thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15794963

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15794963

Country of ref document: EP

Kind code of ref document: A2